This episode reviews the 2025 ACE consensus approach to cost conscious obesity pharmacotherapy, emphasizing access driven treatment sequencing, payer mandated step therapy, and stage based medication selection for adiposity based chronic disease. Focus is placed on balancing clinical efficacy, affordability, and long term sustainability, with escalation and override strategies guided by therapeutic response and the presence of obesity related complications.